NDC 80425-0155-01 - Cyclobenzaprine HCL
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 80425-0155
- Requested NDC
- 80425-0155-01
- Package NDCs from labels
- 80425-0155-4, 80425-0155-1, 80425-0155-3, 80425-0155-2, 80425-0155-5, 80425-0155-01
- Manufacturer
- Advanced Rx Pharmacy of Tennessee, LLC
- Effective date
- 2024-12-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Cyclobenzaprine HCL - Advanced Rx Pharmacy of Tennessee, LLC | Advanced Rx Pharmacy of Tennessee, LLC | 2024-12-31 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 80425-0155-1 | Cyclobenzaprine HCL | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 9 | |
| 80425-0155-2 | Cyclobenzaprine HCL | 60 in 1 BOTTLE | TABLET, FILM COATED | 60 | 9 | |
| 80425-0155-3 | Cyclobenzaprine HCL | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 9 | |
| 80425-0155-4 | Cyclobenzaprine HCL | 120 in 1 BOTTLE | TABLET, FILM COATED | 120 | 9 | |
| 80425-0155-5 | Cyclobenzaprine HCL | 180 in 1 BOTTLE | TABLET, FILM COATED | 180 | 9 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 80425-0155 | CYCLOBENZAPRINE HCL TABLET, FILM COATED [ADVANCED RX PHARMACY OF TENNESSEE, LLC] | 9 | Current NDC, Legacy NDC, 5 package rows | 20250101_c859f63a-09de-4eec-e053-2a95a90a312f.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 80425-0155-1 | EA - Each | 80425-0155 | f4bcb5d0-e79e-475a-abc2-3f28285e7901 | 1 | 2023-03-13 |
| 80425-0155-2 | EA - Each | 80425-0155 | ff5212cb-fd0d-4c91-9128-b6d93df2f0a5 | 1 | 2023-03-13 |
| 80425-0155-3 | EA - Each | 80425-0155 | 852908d7-d274-45fc-92c2-ffaa1f1c5180 | 1 | 2023-03-13 |
| 80425-0155-4 | EA - Each | 80425-0155 | c18b3c89-d4bf-4582-8fb2-7d8d6de5e2ad | 1 | 2023-03-13 |
| 80425-0155-5 | EA - Each | 80425-0155 | 3ea3d38f-4c76-4368-bd3d-7ea8652826ad | 1 | 2023-06-06 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | REMEDYREPACK INC. | 51d85ea8-8317-4a76-a108-20383f118ad4 | 2026-07-10 | Warnings, Adverse reactions | ANDA213324 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE | Cipla USA Inc. | 575a31fb-04c5-4001-88a7-c33adbacc6a8 | 2026-07-08 | Warnings, Adverse reactions | 828320 828348 0VE05JYS2P |
| Cyclobenzaprine HCL | CYCLOBENZAPRINE HCL | Direct_Rx | 55683c5c-0f86-9a26-e063-6294a90a8e8c | 2026-07-01 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Proficient Rx LP | dfe7288c-a477-4f32-a9ab-00cc981a1a57 | 2026-07-01 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | St. Mary's Medical Park Pharmacy | 16ed7d7e-862f-db36-e063-6394a90a02a5 | 2026-06-26 | Warnings, Adverse reactions | ANDA213324 828299 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals,Inc. | 106d9730-5938-8f27-e063-6294a90adc68 | 2026-06-23 | Warnings, Adverse reactions | ANDA213324 828320 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | ST. MARY'S MEDICAL PARK PHARMACY | fe81c68d-a579-4fe9-e053-6294a90a7bc0 | 2026-05-29 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Major Pharmaceuticals | 508e310e-067a-4f95-869a-e1da49aabe94 | 2026-05-21 | Warnings, Adverse reactions | 828320 828348 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | ST. MARY'S MEDICAL PARK PHARMACY | 00b20a8c-debd-e930-e063-6394a90a7ed0 | 2026-05-20 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE | NuCare Pharmaceuticals, Inc. | 4fbbc5b6-7aac-34e5-e054-00144ff88e88 | 2026-05-19 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE | NuCare Pharmaceuticals, Inc. | 4a2b5f25-a333-15f3-e054-00144ff8d46c | 2026-05-05 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Teva Pharmaceuticals USA, Inc. | 1d9e34cc-eee9-4147-abf8-c810a80e39d2 | 2026-05-01 | Warnings, Adverse reactions | 828299 828320 828348 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Proficient Rx LP | ae3a3f5c-fb64-4a43-be88-a2fc7c298ac1 | 2026-05-01 | Warnings, Adverse reactions | 828299 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Coupler LLC | 5023b8a5-c9df-84a4-e063-6294a90a9606 | 2026-04-23 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | QPharma, Inc. | 4dcbdf8f-37ce-0f90-e063-6394a90ae83c | 2026-04-10 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | NuCare Pharmaceuticals, Inc. | 2f89c8f6-7f3c-8396-e063-6294a90a643e | 2026-04-06 | Warnings, Adverse reactions | 828299 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Sportpharm LLC | 24653b10-bdf0-47c5-a1f4-dc25f3b86032 | 2026-04-03 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
| Cyclobenzaprine hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Preferred Pharmaceuticals Inc. | 348c7ad4-b380-4b78-88f4-106b94079f52 | 2026-04-01 | Warnings, Adverse reactions | ANDA213324 828348 0VE05JYS2P |
| CYCLOBENZAPRINE HYDROCHLORIDE | CYCLOBENZAPRINE HYDROCHLORIDE | Preferred Pharmaceuticals Inc. | e4e8bab3-c5e7-4d2b-9692-ee6c6799b120 | 2026-04-01 | Warnings, Adverse reactions | 828320 0VE05JYS2P |
| Cyclobenzaprine Hydrochloride | CYCLOBENZAPRINE HYDROCHLORIDE | Preferred Pharmaceuticals Inc. | 014dd648-5b84-4d1d-80fc-a467e2d741ef | 2026-04-01 | Warnings, Adverse reactions | 828348 0VE05JYS2P |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.